TrialThe lancet. Diabetes & endocrinology2021

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.

Hiddo J L Heerspink et al.PubMed ↗Publisher ↗

No numbers read from the abstract.